Russian pharmaceutical companies have increased the number of clinical trials by almost a third since March 2022, from 395 in March to 525 now, which was reported by the press service of the Ministry of Industry and Trade of the Russian Federation.
“Our companies have increased the number of clinical trials by almost a third since March (from 395 in March to 525 now). Now more than 50 original domestic drugs are at various stages of development (including those for the treatment of spinal muscular atrophy, tumors, leukemias, and immunotherapy for oncological diseases),” the press service of TASS quotes.
In addition, over 7 months, Russian pharmaceutical manufacturers have registered more than 740 drugs in various forms, which accounts for more than 80% of all registration certificates issued during this period.
“That is, the industry is able to ensure the introduction of new products to the market,” the ministry stated.
The RBC publication previously reported, referring to the bulletin of the Association of Clinical Research Organizations (ACRO), that for six months of this year in Russia, almost 50% of previously planned trials of innovative drugs were not implemented or were suspended. The Association of Clinical Research Organizations (ACRO) is also confident that the number of frozen clinical trials is going to increase if the geopolitical situation remains the same.
As Russia’s Ministry of Industry and Trade stressed, ACRO includes only foreign companies.
